EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Multizentrische Studie

Long‐term follow‐up of dose‐dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second‐line treatment of relapsed/refractory classical Hodgkin lymphoma

Ryan C Lynch iD, Ryan D Cassaday, Stephen D Smith, Andrew J Cowan iD, Edus H Warren, Mazyar S Shadman, Brian G Till, Chaitra S Ujjani iD, Karolyn Morris, Heather Rasmussen, Jenna Voutsinas, Ajay K Gopal

British Journal of Haematology · 2025

DOI: 10.1111/bjh.70052 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Ryan C Lynch und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology Oncology, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Hodgkin Disease, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 19 Literaturangaben. Gefördert von: Seagen, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hodgkin DiseaseAntineoplastic Combined Chemotherapy ProtocolsHumansBrentuximab VedotinEtoposideCarboplatinIfosfamideFemaleMaleAdultMiddle AgedFollow-Up StudiesAdolescentAgedYoung AdultRecurrenceSalvage Therapy

Stichwörter der Autor:innen

Hodgkin's lymphomaantibody therapylymphomas

Substanzen

Brentuximab VedotinEtoposideCarboplatinIfosfamide

Autor:innen und Institutionen

  • Division of Hematology Oncology, University of Washington, Seattle, Washington, USA.
  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.

ORCID-Profile: Ryan C Lynch, Andrew J Cowan, Chaitra S Ujjani

Förderung

  • Seagen
  • NCI NIH HHS

Zitieren

APA

Lynch, R. C., Cassaday, R. D., Smith, S. D., Cowan, A. J., Warren, E. H., Shadman, M. S., Till, B. G., Ujjani, C. S., Morris, K., Rasmussen, H., Voutsinas, J., & Gopal, A. K. (2025). Long‐term follow‐up of dose‐dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second‐line treatment of relapsed/refractory classical Hodgkin lymphoma. British Journal of Haematology. https://doi.org/10.1111/bjh.70052

Vancouver

Lynch RC, Cassaday RD, Smith SD, Cowan AJ, Warren EH, Shadman MS, et al. Long‐term follow‐up of dose‐dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second‐line treatment of relapsed/refractory classical Hodgkin lymphoma. British Journal of Haematology. 2025. doi:10.1111/bjh.70052

BibTeX
@article{Lynch2025,
  author = {Lynch, Ryan C and Cassaday, Ryan D and Smith, Stephen D and Cowan, Andrew J and Warren, Edus H and Shadman, Mazyar S and Till, Brian G and Ujjani, Chaitra S and Morris, Karolyn and Rasmussen, Heather and Voutsinas, Jenna and Gopal, Ajay K},
  title = {Long‐term follow‐up of dose‐dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second‐line treatment of relapsed/refractory classical Hodgkin lymphoma},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.70052}
}
Kostenlos starten →